- Home
- ACIC vs ARCT Comparison
ACIC vs ARCT Comparison
Compare ACIC & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIC
- ARCT
- Stock Information
- Founded
- ACIC 1999
- ARCT 2013
- Country
- ACIC United States
- ARCT United States
- Employees
- ACIC N/A
- ARCT N/A
- Industry
- ACIC Property-Casualty Insurers
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- ACIC Finance
- ARCT Health Care
- Exchange
- ACIC Nasdaq
- ARCT Nasdaq
- Market Cap
- ACIC 556.0M
- ARCT 298.3M
- IPO Year
- ACIC N/A
- ARCT N/A
- Fundamental
- Price
- ACIC $11.04
- ARCT $13.78
- Analyst Decision
- ACIC Buy
- ARCT Strong Buy
- Analyst Count
- ACIC 1
- ARCT 8
- Target Price
- ACIC $16.00
- ARCT $52.83
- AVG Volume (30 Days)
- ACIC 286.2K
- ARCT 484.1K
- Earning Date
- ACIC 08-06-2025
- ARCT 08-04-2025
- Dividend Yield
- ACIC 4.53%
- ARCT N/A
- EPS Growth
- ACIC 3.21
- ARCT N/A
- EPS
- ACIC 1.49
- ARCT N/A
- Revenue
- ACIC $302,261,000.00
- ARCT $143,680,000.00
- Revenue This Year
- ACIC N/A
- ARCT N/A
- Revenue Next Year
- ACIC $37.63
- ARCT $34.79
- P/E Ratio
- ACIC $7.50
- ARCT N/A
- Revenue Growth
- ACIC 23.92
- ARCT 15.38
- 52 Week Low
- ACIC $8.82
- ARCT $8.04
- 52 Week High
- ACIC $15.08
- ARCT $25.88
- Technical
- Relative Strength Index (RSI)
- ACIC 54.89
- ARCT 58.14
- Support Level
- ACIC $10.64
- ARCT $12.65
- Resistance Level
- ACIC $11.23
- ARCT $14.09
- Average True Range (ATR)
- ACIC 0.30
- ARCT 0.94
- MACD
- ACIC 0.08
- ARCT 0.05
- Stochastic Oscillator
- ACIC 83.19
- ARCT 64.60
About ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.